Drug · FAERS side-effect profile with label screen
Iodium side effects: what 2,806 FDA adverse event reports show
Drug class
Not stated in label
Who reports
2,806 reports · 47% serious · 118 with death outcome · 85% female
openFDA FAERS counts, all years, deduplication not applied
Used for
Temporarily relieves occasional physical weakness caused by illness, cold hands and feet, weakness and shortness of breath when climbing, and nasal discomfort. CLAIMS BASED ON TRADITIONAL HOMEOPATHIC PRACTICE, NOT ACCEPTED MEDICAL EVIDENCE. NOT FDA EVALUATED. This product is not intended to diagnose, treat, cure, or prevent any disease.
FDA label, Indications and Usage
Boxed warning
None in the current label
How to read this page. FAERS is a spontaneous-reporting system: counts are not incidence rates and a signal is not proof of causation.
Each reaction below is run through an automated screen — is the term in the FDA label (known), in the indications (the disease being treated), an administrative/coding term, or none of these (unlabeled)?
That screen is mechanical text matching, not a causality assessment. The 30 hand-written Bradford Hill assessments are on the causality assessment page. Not medical advice.
Causality screen of the 40 strongest signals
Reporting / coding artifact 1Lab value / disease marker 2No label text to screen 37
What the badges mean
- Reporting / coding artifact An administrative, monitoring or exposure term (product issue, off-label use, 'test normal', overdose...). Not a biological reaction; a high PRR here reflects how reports are coded.
- Lab value / disease marker A laboratory result, investigation or disease-activity marker (antibody positive, CRP abnormal, swollen joint count) not described in the label. These usually mirror the monitored disease or testing protocol rather than a drug effect; not screened further.
- Not in label — unassessed Not found in the label text, not an artifact pattern. This is a genuine candidate for a formal causality assessment (Bradford Hill / WHO-UMC); it has NOT had one here.
- No label text to screen No validated FDA label was retrievable for this product, so the screen could not run. Disproportionality only.
Strongest disproportionality signals
Flagged terms (PRR ≥ 2, χ² ≥ 4, n ≥ 10), ranked by PRR; infinite PRRs (no comparator reports) excluded. The EBGM column is a second, shrinkage-based estimate (MGPS) with its 5th percentile EB05 and the BCPNN IC025; a pair flagged by PRR alone is marked PRR-only and should be read as fragile. The strata column recomputes the PRR on serious reports only and flags pairs whose reports are unusually skewed by sex or come mostly from consumers rather than clinicians. 170 further terms are in the interactive explorer. Reaction links open the term's cross-drug page.
Show:
| Reaction | Reports | PRR 95% CI · ROR · χ²/p | EBGM EB05 · IC025 | Label screen | Serious-only & strata | Trial cross-check |
|---|---|---|---|---|---|---|
| Thyroid disorder | 23 | 11.2 7.4–16.8ROR 11.2 · χ² 203 / p 3e-46 | 10.3 EB05 6.9 · IC025 +2.5 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 14.0 · 82% consumer | no trial data cached |
| Hereditary angioedema | 13 | 9.3 5.4–15.9ROR 9.3 · χ² 88 / p 4e-21 | 7.7 EB05 4.5 · IC025 +1.9 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 12.4 | no trial data cached |
| Tooth abscess | 11 | 8.1 4.5–14.5ROR 8.1 · χ² 61 / p 3e-15 | 6.4 EB05 3.7 · IC025 +1.6 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 12.9 | no trial data cached |
| Intervertebral disc degeneration | 10 | 8.0 4.3–14.9ROR 8.1 · χ² 55 / p 7e-14 | 6.3 EB05 3.5 · IC025 +1.5 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 9.0 | no trial data cached |
| Poor venous access | 11 | 8.0 4.4–14.4ROR 8.0 · χ² 60 / p 4e-15 | 6.3 EB05 3.7 · IC025 +1.6 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious n=11 | no trial data cached |
| Blood triglycerides increased | 18 | 7.6 4.8–12.0ROR 7.6 · χ² 97 / p 4e-23 | 6.6 EB05 4.3 · IC025 +1.9 3/3 methods agree | Lab value / disease marker | serious PRR 13.8 | no trial data cached |
| Bladder disorder | 10 | 7.5 4.0–14.0ROR 7.5 · χ² 50 / p 7e-13 | 5.9 EB05 3.3 · IC025 +1.4 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious n=6 | no trial data cached |
| Synovitis | 15 | 6.2 3.8–10.3ROR 6.2 · χ² 61 / p 4e-15 | 5.3 EB05 3.4 · IC025 +1.5 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 8.0 | no trial data cached |
| Fracture | 15 | 5.9 3.6–9.8ROR 5.9 · χ² 57 / p 3e-14 | 5.1 EB05 3.3 · IC025 +1.5 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 7.9 | no trial data cached |
| Sleep apnoea syndrome | 15 | 5.9 3.5–9.7ROR 5.9 · χ² 56 / p 4e-14 | 5.0 EB05 3.2 · IC025 +1.5 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 8.0 | no trial data cached |
| Head discomfort | 13 | 5.5 3.2–9.5ROR 5.5 · χ² 44 / p 2e-11 | 4.7 EB05 2.9 · IC025 +1.3 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 6.5 | no trial data cached |
| Gastroenteritis viral | 13 | 5.4 3.1–9.2ROR 5.4 · χ² 42 / p 5e-11 | 4.6 EB05 2.9 · IC025 +1.3 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 11.5 | no trial data cached |
| Heart rate irregular | 16 | 5.3 3.2–8.6ROR 5.3 · χ² 51 / p 4e-13 | 4.6 EB05 3.0 · IC025 +1.4 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 5.8 | no trial data cached |
| Bone pain | 41 | 5.2 3.9–7.1ROR 5.3 · χ² 136 / p 9e-32 | 4.9 EB05 3.8 · IC025 +1.8 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 8.3 · ♀ 62% (drug 85%) | no trial data cached |
| Osteoarthritis | 29 | 5.1 3.6–7.3ROR 5.1 · χ² 92 / p 5e-22 | 4.7 EB05 3.5 · IC025 +1.6 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 6.5 · ♀ 56% (drug 85%) | no trial data cached |
| Blood cholesterol increased | 30 | 4.8 3.4–6.9ROR 4.9 · χ² 87 / p 6e-21 | 4.5 EB05 3.3 · IC025 +1.6 3/3 methods agree | Lab value / disease marker | serious PRR 6.8 | no trial data cached |
| Hypothyroidism | 19 | 4.5 2.8–7.0ROR 4.5 · χ² 48 / p 3e-12 | 4.1 EB05 2.8 · IC025 +1.3 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 5.4 | no trial data cached |
| Tooth disorder | 13 | 4.3 2.5–7.5ROR 4.4 · χ² 30 / p 2e-8 | 3.8 EB05 2.4 · IC025 +1.0 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 4.2 | no trial data cached |
| Pain in jaw | 16 | 4.2 2.6–6.9ROR 4.2 · χ² 36 / p 9e-10 | 3.8 EB05 2.5 · IC025 +1.1 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 5.2 | no trial data cached |
| Retching | 12 | 4.2 2.4–7.4ROR 4.2 · χ² 26 / p 1e-7 | 3.7 EB05 2.3 · IC025 +0.9 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 6.8 | no trial data cached |
| Joint injury | 12 | 4.2 2.4–7.4ROR 4.2 · χ² 26 / p 2e-7 | 3.7 EB05 2.3 · IC025 +0.9 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 5.0 | no trial data cached |
| Gallbladder disorder | 10 | 4.2 2.2–7.8ROR 4.2 · χ² 21 / p 2e-6 | 3.6 EB05 2.1 · IC025 +0.8 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 5.6 | no trial data cached |
| Sinus disorder | 11 | 4.1 2.3–7.5ROR 4.2 · χ² 23 / p 7e-7 | 3.6 EB05 2.2 · IC025 +0.8 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 6.0 | no trial data cached |
| Fibromyalgia | 13 | 4.0 2.3–6.9ROR 4.0 · χ² 26 / p 1e-7 | 3.6 EB05 2.2 · IC025 +0.9 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 5.0 | no trial data cached |
| Oral pain | 12 | 4.0 2.3–7.0ROR 4.0 · χ² 24 / p 5e-7 | 3.5 EB05 2.2 · IC025 +0.9 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 3.0 | no trial data cached |
| Therapeutic response unexpected | 24 | 4.0 2.7–5.9ROR 4.0 · χ² 51 / p 5e-13 | 3.7 EB05 2.6 · IC025 +1.2 3/3 methods agree | Reporting / coding artifact | serious PRR 8.0 | no trial data cached |
| Eructation (belching) | 10 | 3.9 2.1–7.3ROR 3.9 · χ² 19 / p 6e-6 | 3.4 EB05 2.0 · IC025 +0.7 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious n=3 | no trial data cached |
| Hypersomnia | 15 | 3.9 2.4–6.5ROR 3.9 · χ² 30 / p 2e-8 | 3.5 EB05 2.3 · IC025 +1.0 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 2.9 | no trial data cached |
| Head injury | 16 | 3.8 2.3–6.2ROR 3.8 · χ² 30 / p 2e-8 | 3.5 EB05 2.3 · IC025 +1.0 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 5.0 | no trial data cached |
| Gait disturbance | 93 | 3.6 3.0–4.4ROR 3.7 · χ² 175 / p 2e-40 | 3.6 EB05 3.0 · IC025 +1.5 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 3.8 · 77% consumer | no trial data cached |
| Pollakiuria (frequent urination) | 20 | 3.6 2.3–5.6ROR 3.6 · χ² 35 / p 2e-9 | 3.4 EB05 2.3 · IC025 +1.0 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 4.4 · 70% consumer | no trial data cached |
| Dry eye | 23 | 3.5 2.4–5.3ROR 3.6 · χ² 40 / p 2e-10 | 3.3 EB05 2.4 · IC025 +1.1 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 5.7 | no trial data cached |
| Balance disorder | 41 | 3.5 2.6–4.8ROR 3.6 · χ² 72 / p 8e-18 | 3.4 EB05 2.6 · IC025 +1.3 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 3.2 | no trial data cached |
| Dysphonia | 27 | 3.5 2.4–5.0ROR 3.5 · χ² 45 / p 1e-11 | 3.3 EB05 2.4 · IC025 +1.1 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 2.7 | no trial data cached |
| Eye swelling | 17 | 3.4 2.1–5.5ROR 3.5 · χ² 27 / p 1e-7 | 3.2 EB05 2.1 · IC025 +0.9 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 3.1 | no trial data cached |
| Intervertebral disc protrusion | 10 | 3.4 1.8–6.3ROR 3.4 · χ² 15 / p 6e-5 | 3.0 EB05 1.8 · IC025 +0.5 | No label text to screen label has no adverse-reaction text | serious PRR 3.4 | no trial data cached |
| Musculoskeletal pain | 24 | 3.4 2.3–5.1ROR 3.4 · χ² 38 / p 3e-10 | 3.2 EB05 2.3 · IC025 +1.0 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 3.9 | no trial data cached |
| Anger | 15 | 3.3 2.0–5.5ROR 3.3 · χ² 22 / p 1e-6 | 3.1 EB05 2.0 · IC025 +0.7 | No label text to screen label has no adverse-reaction text | serious PRR 5.3 | no trial data cached |
| Abasia | 11 | 3.3 1.8–5.9ROR 3.3 · χ² 15 / p 5e-5 | 3.0 EB05 1.8 · IC025 +0.6 | No label text to screen label has no adverse-reaction text | serious PRR 3.5 | no trial data cached |
| Panic attack | 16 | 3.3 2.0–5.3ROR 3.3 · χ² 23 / p 8e-7 | 3.0 EB05 2.0 · IC025 +0.8 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 4.0 | no trial data cached |
Trial evidence (ClinicalTrials.gov)
Trial cross-check not yet run for this drug (ClinicalTrials.gov pull covers the 800 most-reported drugs first).
Most frequently reported reactions
By raw co-report count, regardless of disproportionality. Common terms here are often the illness itself or generic outcomes.
| Reaction | Reports | PRR 95% CI · ROR · χ²/p | EBGM EB05 · IC025 | Label screen | Serious-only & strata | Trial cross-check |
|---|---|---|---|---|---|---|
| Feeling abnormal | 98 | 3.0 2.5–3.7ROR 3.1 · χ² 134 / p 3e-31 | 3.0 EB05 2.5 · IC025 +1.3 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 4.0 · 78% consumer | no trial data cached |
| Gait disturbance | 93 | 3.6 3.0–4.4ROR 3.7 · χ² 175 / p 2e-40 | 3.6 EB05 3.0 · IC025 +1.5 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 3.8 · 77% consumer | no trial data cached |
| Myalgia (muscle pain) | 67 | 2.9 2.3–3.7ROR 3.0 · χ² 85 / p 2e-20 | 2.9 EB05 2.4 · IC025 +1.1 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 2.8 · 71% consumer | no trial data cached |
| Injection site pain (pain where injected) | 48 | 1.2 0.9–1.6ROR 1.2 · χ² 1 / p 0.138 | 1.2 EB05 0.9 · IC025 -0.2 PRR-only: not supported by EBGM or IC | No label text to screen label has no adverse-reaction text | serious PRR 2.7 | no trial data cached |
| Influenza | 47 | 3.1 2.4–4.2ROR 3.2 · χ² 67 / p 1e-16 | 3.1 EB05 2.4 · IC025 +1.1 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 4.8 | no trial data cached |
| Balance disorder | 41 | 3.5 2.6–4.8ROR 3.6 · χ² 72 / p 8e-18 | 3.4 EB05 2.6 · IC025 +1.3 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 3.2 | no trial data cached |
| Bone pain | 41 | 5.2 3.9–7.1ROR 5.3 · χ² 136 / p 9e-32 | 4.9 EB05 3.8 · IC025 +1.8 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 8.3 · ♀ 62% (drug 85%) | no trial data cached |
| Rheumatoid arthritis | 37 | 2.4 1.8–3.4ROR 2.5 · χ² 30 / p 2e-8 | 2.4 EB05 1.8 · IC025 +0.7 | No label text to screen label has no adverse-reaction text | serious PRR 3.1 · ♀ 61% (drug 85%) | no trial data cached |
| Flushing | 36 | 2.6 1.9–3.6ROR 2.7 · χ² 35 / p 2e-9 | 2.6 EB05 1.9 · IC025 +0.8 | No label text to screen label has no adverse-reaction text | serious PRR 4.5 | no trial data cached |
| Drug dose omission | 30 | 1.3 0.9–1.9ROR 1.3 · χ² 2 / p 0.067 | 1.3 EB05 1.0 · IC025 -0.2 PRR-only: not supported by EBGM or IC | Reporting / coding artifact | serious PRR 2.3 · 76% consumer | no trial data cached |
| Hot flush (hot flashes) | 30 | 3.0 2.1–4.2ROR 3.0 · χ² 37 / p 5e-10 | 2.9 EB05 2.1 · IC025 +0.9 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 4.3 | no trial data cached |
| Blood cholesterol increased | 30 | 4.8 3.4–6.9ROR 4.9 · χ² 87 / p 6e-21 | 4.5 EB05 3.3 · IC025 +1.6 3/3 methods agree | Lab value / disease marker | serious PRR 6.8 | no trial data cached |
| Product quality issue | 29 | 1.6 1.1–2.3ROR 1.6 · χ² 6 / p 0.007 | 1.6 EB05 1.2 · IC025 +0.1 | Reporting / coding artifact | serious PRR 2.0 | no trial data cached |
| Osteoarthritis | 29 | 5.1 3.6–7.3ROR 5.1 · χ² 92 / p 5e-22 | 4.7 EB05 3.5 · IC025 +1.6 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 6.5 · ♀ 56% (drug 85%) | no trial data cached |
| Dysphonia | 27 | 3.5 2.4–5.0ROR 3.5 · χ² 45 / p 1e-11 | 3.3 EB05 2.4 · IC025 +1.1 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 2.7 | no trial data cached |
Unlabeled candidate signals
Every screened signal with n ≥ 20 was either labeled, an indication term, or an artifact pattern — no unlabeled candidate stood out in the top signals.
Want to assess one of these properly? The runbook describes the Bradford Hill / trial-evidence workflow used on the assessment page, and handoff_top1000_signals.csv lists the strongest unassessed pairs across all drugs.
Common questions
What are the most reported side effects of Iodium?
In FDA FAERS, the most frequently co-reported reaction terms for Iodium are feeling abnormal, gait disturbance, myalgia, injection site pain, influenza, balance disorder. These are report counts, not rates: FAERS has no denominator, reporting is voluntary and uneven, and a term can be reported because of the illness being treated rather than the drug.
Does Iodium have an FDA boxed warning?
No. The FDA label retrieved for Iodium has no boxed warning; see the label's Warnings and Precautions for the recognised risks.
Do FAERS signals prove that Iodium causes these side effects?
No. A disproportionality signal (PRR, ROR) means a reaction is reported more often with this drug than with others in the database. That can reflect a real effect, but also the disease being treated, stimulated reporting after news or litigation, co-medications, or how reports are coded. Causality needs temporality, dose-response, biological plausibility, consistency across data sources and, ideally, trial or cohort evidence. This page screens each term against the FDA label and ClinicalTrials.gov results; it does not establish causation.
Sources & methods
- FDA label via openFDA (set ID 2f995812-b64c-30ad-e063-6394a90aa4bb, effective 20250305; matched on
openfda.generic_name.exact:"IODIUM") - Bayesian shrinkage measures computed offline over all 1,317,300 cached pairs: BCPNN information component (IC, with Norén closed-form IC025) and MGPS empirical-Bayes geometric mean (EBGM, EB05) with a two-component gamma prior fitted by maximum marginal likelihood (α₁=0.57, β₁=0.02, α₂=1.42, β₂=0.70, w=0.17); unstratified
- FAERS pair statistics from the OpenPV build of 2026-09-14 (openFDA
count=aggregation, fieldpatient.drug.openfda.generic_name.exact, 210 reaction terms, min 3 co-reports); PRR/ROR with 95% CI, chi-square with Yates correction - Serious-only and stratified counts (serious:1, patient.patientsex, primarysource.qualification) from openFDA count queries; serious-only PRR uses the drug serious report total and the term global serious total (N_serious=11,882,979); strata shown only when n ≥ 20
- Seriousness and sex counts from openFDA
count=serious,patient.patientsex,seriousnessdeath
Page generated 2026-10-08. Label and PubChem text are retrieved automatically and may lag the current label; always check the current prescribing information. OpenPV is a beta research tool of the Open Source Medicine Foundation.